Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREAMM-10 in transplant-ineligible newly diagnosed multiple myeloma
2024-516030-35-00Phase 3Authorised
- Sponsor
- GSK
- Start
- Apr 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial of belantamab mafodotin in multiple myeloma (MM) (2 arms), sponsored by GSK. Primary endpoints: Progression-free survival and MRD negative status. Planned start Apr 2025; status: authorised.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-516030-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516030-35-00.